| Objective: To explore the role of Liraglutide on the body fat composition of obese patients with type 2 diabetes mellitus(T2DM) among the Uygur nationality in Xinjiang after 12 weeks. Methods: Obese patients with type 2 diabetes mellitus were enrolled in the study of 67 patients who had poorly glycemic after treated with metformin alone.These patients were randomly divided into metformin monotherapy group and metformin combination Liraglutide treatment group, the treatment time was 12 weeks. At the beginning and end of the experiment,to measure respectively the abdominal visceral adipose area(VA), percentage of body fat(PBF), body fat weight, and measurement of nitric oxide(NO), fasting blood glucose(FBG), glycosylated hemoglobin(HbA1C), free fatty acid(FFA) and other related indicators by Inbody 720 body composition analyzer,then to calculate body mass index(BMI), waist hip ratio(WHR), take the case-control method for analysis.Results: after treatment for 12 weeks,metformin combination Liraglutide group reduced weight was significantly greater than that of single metformin group [-2.67 kg vs-1.48 kg, 95% CI0.86 ~ 1.52, P = 0.00)],and metformin combination Liraglutide group had significantly lower body fat [-2.12 kg vs-0.85 kg, 95%CI(0.93 ~ 1.62), p < 0.01] and visceral fat area [-17.07 cm2 vs-0.79 cm2, 95% CI(13.18~ 19.07),(p < 0.01). The metformin combination Liraglutide group promoted nitric oxide production was also greater than metformin, the two groups were increased by 22.13umol/L and 16.05 umol/L respectively compared with baseline. Average BMI level of metformin combined with Liraglutide group from 32.77kg/m2 fell to 31.42 kg/m2, and waistline reduced by 3.8 cm, and HbAlc level fell by 2.04%, fasting blood glucosedecreased by 3.26mmol/L. Conclusion: Liraglutide in treatment of patients with type 2diabetes not only can reduce the blood sugar, blood lipid,but also and can reduce the body weight and visceral fat, improve endothelial function. |
PDF Full Text Request